NCT05876364进行中（未招募）1 期
A Phase 1, Dose-escalation, Multi-center, Open-label, Study to Evaluate the Safety, Reactogenicity and Immunogenicity of a Preventive SARS-CoV-2 Vaccine (QTP104) in Healthy Adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Quratis Inc.
- 入组人数
- 36
- 试验地点
- 4
- 主要终点
- Adverse event(solicited local / systemic AEs)
研究概览
简要总结
This study is to evaluate the safety, reactogenicity, and immunogenicity of the QTP104 vaccine against SARS-CoV-2 infection in healthy adults.
详细描述
This study is designed to evaluate the safety, immunogenicity of 3 doses of QTP104. The reason for including 3 doses were to further explore the immunogenicity of these dose levels. This clinical trial is an open label and does not apply to randomized assignment procedures. This study is an open label and does not apply to the maintenance and release procedure of double-blinding. The selection of healthy adults is to confirm the safety of dose-escalation through phase 1 clinical trials.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult male or female aged 19 to 55 years at the screening visit (Visit 1)
- •Subject with a Body Mass Index (BMI) of 18kg/m2 or more and 30kg/m2 or less at the screening visit (Visit 1)
- •Women of childbearing potential who have not undergone sterilization must agree to use an appropriate method of contraception* during this clinical trial period and up to 3 months after the end of administration of the investigational drug and there must be evidence of non-fertility at the screening visit (Visit 1)
- •Men who has not undergone a vasectomy must consent to the use of barrier contraception (i.e., condoms) and if both subejct and partner agree to use an appropriate method of contraception for the duration of the clinical trial and up to 6 months after the end of investigational drug administration
- •Subject who can collect blood and urine during this clinical trial period including the last visit
- •Subject who havs heard the detailed explanation of this clinical trial, have voluntarily decided to participate, and have agreed in writing to abide by the precautions
- •Subject who agrees not to donate blood or transfusion (including whole blood, plasma components, platelet components and platelet plasma components) during the clinical trial period
排除标准
- •[Current disease and medical history]
- •Subject who has identified any acute, chronic, or clinically significant disease as a result of a physical or laboratory examination during a screening visit (Visit 1)
- •Subject who has a history of malignant tumors within the past 5 years
- •Subject who has an immune dysfunction, including immunodeficiency disease, or a family history thereof through a medical history and/or physical examination
- •Subject who has positive SARS-CoV-2 IgG Ab results during screening visit (Visit 1)
- •Subject previously diagnosed with COVID-19
- •Subject with any acute, chronic, or clinically significant disease as a result of physical examination or laboratory examination at the screening visit (Visit 1)
- •Subject with a history of malignancy within 5 years before the first dose of the investigational drug (except for basal cell and squamous cell carcinoma of the skin)
- •Subject with immune dysfunction including immunodeficiency disease through medical history and/or physical examination, or with a family history
- •Subject with a positive result of virus test (hepatitis B test, hepatitis A test, human immunodeficiency virus test, hepatitis C test) at the screening visit (Visit 1)
- •Subject who are significantly abnormal clinically in laboratory tests, electrocardiogram, chest, and X-rays performed at the screening visit (Visit 1) and those who are judged impossible to participate in the clinical trial at the discretion of the investigator
- •Subject with a history of hypersensitivity or severe allergic reaction to vaccine administration [e.g. anaphylaxis, Guillain-Barre syndrome, urticaria*, other clinically significant reactions requiring medical intervention]
- •Urticaria: Those with a history of systemic urticaria within 5 years before administration of investigational drugs
- •Subject with diseases on such systems as hepatobiliary, kidney, nervous system (central or peripheral), respiratory (asthma, pneumonia, etc.), endocrine (uncontrolled diabetes mellitus, hyperlipidemia, etc.), cardiovascular (congestive heart failure, coronary artery disease, myocardial infarction, uncontrolled hypertension) etc.), urinary, psychiatric, musculoskeletal disorders or have a clinically significant history that it is judged to be unable to participate in a clinical trial under the judgment of the investigator
- •Subject with autoimmune diseases including autoimmune hypothyroidism and psoriasis
- •Subject with suspected or history of alcohol or substance abuse 12 months prior to the scheduled screening visit (Visit 1). Alcohol abuse standards are defined as follows:
- •Subject who has had a serious adverse reaction to a drug containing the same component as the investigational drug or has a history of allergy
- •Subject who has had a cough, dyspnea, chills, muscle pain, headache, sore throat, loss of smell or taste and an acute fever in which the body temperature exceeds 37.5°C within 72 hours prior to administration of the clinical trial drug
- •Subject who has been diagnosed with COVID-19 and/or have been confirmed or treated for COVID-19 infection as a result of laboratory tests
- •Subject with a history of previous MERS-CoV or SARS-CoV infection
- •Subject with a history of hereditary or idiopathic angioneurotic edema
- •Subject with a history of organ or bone marrow transplantation
- •[Relating to contraindicated drugs]
- •Subject who has experience in administering an immunosuppressant or immune modifying drug within 6 months prior to administration of an investigational drug
- •Patients with hemophilia who are at risk of serious bleeding when injected intramuscularly or are taking anticoagulants.
- •Subject who has received immunoglobulin or blood-derived products within 3 months prior to administration of the investigational drug or are expected to administer it during the clinical trial period
- •Subject who participated in other clinical trials similar to the investigational drug before the screening visit (Visit 1)
- •Subject with a history of MERS-CoV or SARS-CoV vaccination
- •Subject who haa received or plan to administer the vaccine within 4 weeks before/after administration of this investigational drug
- •Subject with a history of platelet-related disease or hemorrhagic disease, a history of severe bleeding or bruising after intramuscular injection or venipuncture or a person taking anticoagulants
- •If there is a history of dependent administration of psychotropic drugs or narcotic analgesics within 6 months prior to administration of the investigational drug or in case of a mental illness or social condition in which it is difficult to comply with the clinical trial procedure according to the judgment of the investigator
结局指标
主要结局
Adverse event(solicited local / systemic AEs)
时间窗: 7 days after each administration
Incidence rate of expected local and systemic adverse events (solicited local / systemic AEs)
Adverse events(Immediated AEs)
时间窗: 30 minutes after each administration
Incidence rate of immediate adverse events (Immediated AEs)
Adverse event(AESI)
时间窗: 394 days from 0 day
Incidence rate of adverse events of special interest (AESI)
Adverse event(unsolicited AEs)
时间窗: 28 days after each administration
Incidence rate of unexpected adverse events (unsolicited AEs)
Adverse event(SAEs / serious ADRs)
时间窗: 28 days after each administration
Incidence rate of serious adverse events and adverse drug reactions (SAEs / serious ADRs)
次要结局
- Proportion of subjects for seroconversion of IgG antibodies titer of QTP104(Day 0, 29, 57, 180, 394)
- Immunogenicity of QTP104 vaccine as measured by neutralizing antibodies(Day 0, 29, 57, 180, 394)
- Immunogenicity of QTP104 vaccine as measured by IgG ELISA(Day 0, 29, 57, 180, 394)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
4 期
A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in IndiaInfluenza, HumanNCT05648357GlaxoSmithKline250
已完成
1 期
Study to Evaluate Safety and Immunogenicity of DNA Vaccine N-pVAX1 Against Crimean Congo Hemorrhagic FeverCrimean Congo Hemorrhagic FeverNCT06684431Karolinska Institutet15
已完成
1 期
A Study to Determine the Safety and Immunogenicity of a Candidate MAP Vaccines ChAdOx2 HAV and MVA in Healthy Adult VolunteersMycobacterium Avium Subspecies ParatuberculosisCrohn DiseaseNCT03027193University of Oxford28
已完成
1 期
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)Marginal Zone LymphomaFollicular LymphomaChronic Lymphocytic LeukemiaDiffuse Large B-cell LymphomaRichter Transformation LymphomaBurkitt LymphomaLymphoplasmacytoid LymphomaT-cell Non-Hodgkin LymphomaAcute Lymphoid LeukemiaWaldenstrom MacroglobulinemiaAcute Myeloid LeukemiaMantle Cell LymphomaNCT03833180VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)91
已完成
1 期
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.Solid TumorsNCT02503774MedImmune LLC192